The HYALEX Knee Implant’s design allows for treatment of patients with varying degrees of cartilage damage. Credit: sasirin pamai/Shutterstock.com.

Hyalex Orthopaedics has announced the successful treatment of the first patients in the first-in-human clinical trials with its HYALEX Knee Cartilage System.

The company’s two prospective, multi-centre, single-arm studies, NCT06368700 and NCT06344481, are being carried out in the US and Europe to evaluate the safety and technical performance of the HYALEX system for knee cartilage repair.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The clinical trials are being conducted at Oregon Health & Science University and the Hospital for Special Surgery in the US, as well as the SPORTO Clinic and the Enel-Sport Center for Orthopedics and Rehabilitation in Poland.

The HYALEX Knee Cartilage System is designed to mimic the structure and function of hyaline cartilage, the tissue that allows for smooth joint movement.

 It aims to replace damaged cartilage lesions with a material that offers both strength and lubrication.

Patients enrolled in these two studies undergo regular assessments through imaging, physical exams, and patient-reported outcome measures.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Hyalex president and CEO Carl Vause said: “Our preclinical evaluations and testing of the HYALEX Knee Cartilage System have demonstrated the impressive resilience and durability of this technology.

“The quality of this data and our rigorous test methods were validated with the full FDA IDE approval of the US study. The initiation of these studies is a critical step on the path to providing Hyalex technology to orthopaedic surgeons, allowing them to treat these currently untreated patients.”

The HYALEX Knee Implant’s unique design allows for the treatment of patients with varying degrees of cartilage damage, including those with or without bony involvement. This flexibility could position the HYALEX system as a disruptive technology in orthopaedic materials.

SPORTO Clinic head and University of Lodz orthopaedics and trauma chief Marcin Domzalski said: “Initial assessments of the Hyalex patients I have treated suggest that they are responding positively to the implant procedure and recovering very well. These are very promising results for cartilage patients at this stage of their treatment journey.”

Hyalex Orthopaedics’ cartilage system received the US Food and Drug Administration’s (FDA) breakthrough device designation in 2021.